CL2017002549A1 - Uso de una composición de bismuto-tiol (bt), que sirve para preparar un medicamento útil para el tratamiento de una herida abierta que tiene o que está en riesgo de tener una infección de biopelícula bacteriana. - Google Patents

Uso de una composición de bismuto-tiol (bt), que sirve para preparar un medicamento útil para el tratamiento de una herida abierta que tiene o que está en riesgo de tener una infección de biopelícula bacteriana.

Info

Publication number
CL2017002549A1
CL2017002549A1 CL2017002549A CL2017002549A CL2017002549A1 CL 2017002549 A1 CL2017002549 A1 CL 2017002549A1 CL 2017002549 A CL2017002549 A CL 2017002549A CL 2017002549 A CL2017002549 A CL 2017002549A CL 2017002549 A1 CL2017002549 A1 CL 2017002549A1
Authority
CL
Chile
Prior art keywords
composition
bismuth
thiol
risk
prepare
Prior art date
Application number
CL2017002549A
Other languages
English (en)
Inventor
Brett Hugh James Baker
Original Assignee
Microbion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/023549 external-priority patent/WO2011097347A2/en
Application filed by Microbion Corp filed Critical Microbion Corp
Publication of CL2017002549A1 publication Critical patent/CL2017002549A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N55/00—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
    • A01N55/02—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing metal atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/82—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with three ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

<p>la invención divulga uso de una composición de bismuto-tiol (BT), CARACTERIZADO porque sirve para preparar un medicamento útil para el tratamiento de una herida abierta que tiene o que está en riesgo de tener una infección de biopelícula bacteriana, en donde la composición BT comprende una suspensión monodispersa de micropartículas que comprenden un compuesto de BT, en donde en dicha suspensión, al menos el 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% o 99% de dichas micropartículas tienen un diámetro volumétrico medio de aproximadamente 0,4 μm a aproximadamente 10μm.</p>
CL2017002549A 2010-08-12 2017-10-10 Uso de una composición de bismuto-tiol (bt), que sirve para preparar un medicamento útil para el tratamiento de una herida abierta que tiene o que está en riesgo de tener una infección de biopelícula bacteriana. CL2017002549A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37318810P 2010-08-12 2010-08-12
PCT/US2011/023549 WO2011097347A2 (en) 2010-02-03 2011-02-03 Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses

Publications (1)

Publication Number Publication Date
CL2017002549A1 true CL2017002549A1 (es) 2018-05-11

Family

ID=44356067

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013000430A CL2013000430A1 (es) 2010-08-12 2013-02-12 Metodo para proteger una planta contra un patógeno bacteriano, fúngico o viral porque comprende poner en contacto la planta con bismuto tiol (bt); metodo para superar la resistencia a antibioticos en una planta, en o sobre la cual está presente un patógeno vegetal bacteriano resistente a los antibioticos.
CL2017002549A CL2017002549A1 (es) 2010-08-12 2017-10-10 Uso de una composición de bismuto-tiol (bt), que sirve para preparar un medicamento útil para el tratamiento de una herida abierta que tiene o que está en riesgo de tener una infección de biopelícula bacteriana.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2013000430A CL2013000430A1 (es) 2010-08-12 2013-02-12 Metodo para proteger una planta contra un patógeno bacteriano, fúngico o viral porque comprende poner en contacto la planta con bismuto tiol (bt); metodo para superar la resistencia a antibioticos en una planta, en o sobre la cual está presente un patógeno vegetal bacteriano resistente a los antibioticos.

Country Status (17)

Country Link
EP (1) EP2603083A4 (es)
JP (7) JP2013535506A (es)
KR (6) KR101821833B1 (es)
CN (2) CN105766990B (es)
AU (3) AU2011289338B2 (es)
BR (2) BR112012019286A2 (es)
CA (1) CA2807993C (es)
CL (2) CL2013000430A1 (es)
IL (3) IL224684A (es)
MX (4) MX371047B (es)
NZ (1) NZ606634A (es)
PH (2) PH12013500267A1 (es)
RU (2) RU2013110493A (es)
SG (3) SG10201506131RA (es)
UA (1) UA113616C2 (es)
WO (1) WO2012021754A2 (es)
ZA (1) ZA201301841B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102341105B (zh) 2009-02-03 2014-09-17 微生物公司 用作上皮组织、急性和慢性伤口、细菌生物被膜和其他适应症的抗菌剂的铋硫醇
US9028878B2 (en) 2009-02-03 2015-05-12 Microbion Corporation Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
BR112012019286A2 (pt) * 2010-02-03 2018-06-26 Microbion Corp bismuto-tióis como antisséptico para usos biomédicos, que incluem tratamento de biofilmes bacterianos e outros usos
ES2647499T3 (es) * 2013-03-18 2017-12-21 Theranovis Gmbh & Co. Kg Composición para el cuidado bucal
RU2525200C1 (ru) * 2013-04-09 2014-08-10 Алексей Георгиевич Бородкин Средство для защиты и заживления ран деревьев
KR101703732B1 (ko) * 2013-11-07 2017-02-07 (주)아모레퍼시픽 효소처리 동백나무 씨 오일을 포함하는 항염 조성물
WO2017145142A1 (en) 2016-02-25 2017-08-31 Nobio Ltd. Micro and nanoparticulate compositions comprising anti-microbially active groups
JP7337778B2 (ja) 2017-08-30 2023-09-04 ノビオ リミテッド 抗微生物粒子を含む組成物および医療機器
CN107950536A (zh) * 2017-12-04 2018-04-24 刘志伟 一种含百菌清的杀菌组合物
CN108839186B (zh) * 2018-05-15 2021-02-26 阜南县金威工艺品有限公司 一种桑枝编织品防霉处理方法
JP7564101B2 (ja) 2018-07-31 2024-10-08 マイクロビオン コーポレーション ビスマスチオール組成物及び使用方法
MX2021001276A (es) 2018-07-31 2021-07-15 Microbion Corp Composiciones de bismuto-tiol y metodos para tratar heridas.
KR101990253B1 (ko) * 2018-11-22 2019-06-17 하봉호 컨테이너형 버섯재배장치
CN109997856B (zh) * 2019-04-15 2020-11-03 广西大学 一种小分子化合物的组合物及其应用
CA3143688A1 (en) * 2019-06-17 2020-12-24 Migal Galilee Research Institute Ltd. Stabilized mutants of quorum quenching lactonase and use thereof in treatment of pathogens
KR102126721B1 (ko) * 2019-07-16 2020-06-25 (주)인트론바이오테크놀로지 신규한 엔테로박터 애로진스 박테리오파지 Ent-AEP-1 및 이의 엔테로박터 애로진스 균과 엔테로박터 클로아카 균 증식 억제 용도
JP7458622B2 (ja) * 2019-09-18 2024-04-01 学校法人東京農業大学 抗生物質耐性微生物の耐性を低下させる物質及び抗生物質耐性微生物の耐性を低下させる方法
CN110663672B (zh) * 2019-11-13 2024-04-26 南京林业大学 一种螺纹驱动的根部施药头
US11479655B2 (en) * 2020-01-15 2022-10-25 The Boeing Company Compositions for use with polysulfide sealants and related methods
KR102197719B1 (ko) 2020-05-07 2021-01-04 곽태진 갑오징어 양식 시스템
CN111856546B (zh) * 2020-06-23 2022-07-29 中国辐射防护研究院 一种关于海洋生物灰中Cs-137放化分析的制样方法
CN113969300B (zh) * 2020-07-23 2024-08-23 禾美生物科技(浙江)有限公司 一种桉树叶复合活性提取物工艺及其抗菌应用
CN112640907B (zh) * 2021-01-19 2021-11-16 西南大学 硫辛酸抑制植物真菌致病菌的新用途及防治柑橘果实采后真菌病害的方法
KR102431000B1 (ko) * 2021-07-22 2022-08-11 농업회사법인 주식회사 아그로비즈 아스피린과 벤조치아졸이 포함된 식물의 자가면역 증강제 조성물 및 이를 이용한 이용방법
JP7791348B2 (ja) * 2022-03-22 2025-12-23 オロ・アグリ・ヨーロッパ・ソシエダーデ・アノニマ 農業用組成物
EP4310192A1 (en) * 2022-07-21 2024-01-24 C4Diagnostics Method of determining the existence and/or degree of resistance of microorganisms to antimicrobial agents
CN115323778B (zh) * 2022-08-16 2023-07-18 汕头市润丰纺织科技实业有限公司 壳聚糖-i型胶原氨基酸复合抗菌整理液及其制备方法和抗菌面料
TR2022012983A2 (tr) * 2022-08-17 2022-09-21 Marmara Ueniv Strateji Gelis Dai Bsk Muhasebe Birimi Kemi̇k rahatsizliklari ve/veya kirilmalari i̇çi̇n onarici ve tedavi̇ edi̇ci̇ özelli̇kte bi̇youyumlu bi̇r ürün ve söz konusu ürünün eldesi̇ i̇çi̇n bi̇r yöntem
CN115532295B (zh) * 2022-09-27 2023-07-25 苏州大学 含有Zn-N-C活性中心的纳米材料在去除细菌生物膜中的应用
KR102644907B1 (ko) * 2023-12-01 2024-03-07 (주)신용이엔씨 지반 보강을 위한 친환경 그라우팅용 조성물 및 이의 제조 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809971A (en) * 1955-11-22 1957-10-15 Olin Mathieson Heavy-metal derivatives of 1-hydroxy-2-pyridinethiones and method of preparing same
JP3813644B2 (ja) * 1994-08-29 2006-08-23 英治 安里 ビスマス錯体およびそれを含有する抗菌剤
US6086921A (en) * 1995-04-25 2000-07-11 Wintrop-University Hospital Metal/thiol biocides
US5928671A (en) * 1995-04-25 1999-07-27 Winthrop University Hospital Method and composition for inhibiting bacteria
US6017936A (en) * 1997-03-14 2000-01-25 Arch Chemicals, Inc. Method for producing particles of pyrithione salts and particles so produced
US5999828A (en) * 1997-03-19 1999-12-07 Qualcomm Incorporated Multi-user wireless telephone having dual echo cancellers
AU2003204105B2 (en) * 1997-10-28 2005-11-17 Winthrop-University Hospital Metal/Thiol Biocides
AU2656799A (en) * 1998-02-04 1999-08-23 Winthrop-University Hospital Metal-thiols as imminomodulating agents
US6465015B1 (en) * 1998-02-24 2002-10-15 Arch Chemicals, Inc. Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
TWI245763B (en) * 1998-04-02 2005-12-21 Janssen Pharmaceutica Nv Biocidal benzylbiphenyl derivatives
EP1115289A2 (en) * 1998-09-23 2001-07-18 Phycogen, Inc. Environmentally benign crop protection agents
US6682724B2 (en) * 1999-02-23 2004-01-27 Arch Chemcials, Inc. Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles
US6630172B2 (en) * 2001-01-22 2003-10-07 Kareem I. Batarseh Microbicidal composition containing potassium sodium tartrate
US6582719B2 (en) * 2001-02-02 2003-06-24 The Trustees Of Columbia University In The City Of New York Combinations of antiseptic and antibiotic agents that inhibit the development of resistant microorganisms
JP4357166B2 (ja) * 2002-10-21 2009-11-04 日揮触媒化成株式会社 抗菌・防黴・防藻性組成物
US7381751B2 (en) * 2003-08-26 2008-06-03 Shantha Sarangapani Antimicrobial composition for medical articles
JP4885866B2 (ja) * 2004-10-25 2012-02-29 セロノヴァ バイオサイエンスィズ ジャーマニー ゲーエムベーハー 治療適用および／または診断適用のための充填可能なポリホスファゼン含有粒子、ならびにその調製方法および使用方法
JP4568232B2 (ja) * 2006-01-06 2010-10-27 秀和 西松 人工骨頭保持具
JP2007332040A (ja) * 2006-06-12 2007-12-27 Shinshu Univ カーボンナノチューブを含む抗菌剤とそれを用いた材料及び製剤
US20110008402A1 (en) * 2006-10-13 2011-01-13 Kane Biotech Inc. Souluble b-n-acetylglucoseaminidase based antibiofilm compositions and uses thereof
EP2117611B1 (en) * 2007-01-24 2014-07-30 Cook Medical Technologies LLC Biofilm-inhibiting medical products
US8343536B2 (en) 2007-01-25 2013-01-01 Cook Biotech Incorporated Biofilm-inhibiting medical products
US20080292721A1 (en) * 2007-05-18 2008-11-27 Crudden Joseph J Bioactive acid agrichemical compositrions and use thereof
WO2008150375A1 (en) * 2007-06-01 2008-12-11 Arrow International, Inc. Combined fibrinolytic and antimicrobial catheter and uses thereof
CA2694408C (en) * 2007-07-25 2014-01-07 Varian Medical Systems, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
CN102341105B (zh) * 2009-02-03 2014-09-17 微生物公司 用作上皮组织、急性和慢性伤口、细菌生物被膜和其他适应症的抗菌剂的铋硫醇
BR112012019286A2 (pt) * 2010-02-03 2018-06-26 Microbion Corp bismuto-tióis como antisséptico para usos biomédicos, que incluem tratamento de biofilmes bacterianos e outros usos

Also Published As

Publication number Publication date
JP2016117741A (ja) 2016-06-30
ZA201301841B (en) 2024-10-30
CA2807993C (en) 2023-03-14
CA2807993A1 (en) 2012-02-16
EP2603083A2 (en) 2013-06-19
KR20200015814A (ko) 2020-02-12
JP2020055839A (ja) 2020-04-09
PH12016502498A1 (en) 2018-06-11
MX2013001581A (es) 2013-03-20
CL2013000430A1 (es) 2013-10-04
JP2018076358A (ja) 2018-05-17
KR101821833B1 (ko) 2018-01-25
RU2018108411A (ru) 2019-02-25
SG187801A1 (en) 2013-03-28
KR20190039607A (ko) 2019-04-12
CN105766990B (zh) 2019-08-02
PH12013500267A1 (en) 2017-07-19
JP2020063277A (ja) 2020-04-23
UA113616C2 (xx) 2017-02-27
CN105766990A (zh) 2016-07-20
CN103096720A (zh) 2013-05-08
IL224684A (en) 2016-11-30
JP7097344B2 (ja) 2022-07-07
SG10202001032RA (en) 2020-04-29
BR112013003127A2 (pt) 2016-06-28
EP2603083A4 (en) 2014-10-22
CN103096720B (zh) 2016-03-30
KR20130000386A (ko) 2013-01-02
AU2011289338A1 (en) 2013-03-28
MX395247B (es) 2025-03-25
WO2012021754A3 (en) 2012-05-24
RU2013110493A (ru) 2014-09-20
MX371047B (es) 2020-01-14
SG10201506131RA (en) 2015-09-29
JP6272366B2 (ja) 2018-01-31
AU2018204190A1 (en) 2018-07-05
JP6685991B2 (ja) 2020-04-22
IL258908A (en) 2018-06-28
NZ606634A (en) 2015-01-30
JP2018008971A (ja) 2018-01-18
MX2019001293A (es) 2019-07-04
BR112012019286A2 (pt) 2018-06-26
MX362785B (es) 2019-02-12
KR20130132410A (ko) 2013-12-04
KR102074444B1 (ko) 2020-02-06
KR20180085042A (ko) 2018-07-25
KR101966867B1 (ko) 2019-04-08
WO2012021754A2 (en) 2012-02-16
JP2022003090A (ja) 2022-01-11
IL248446B (en) 2018-05-31
JP2013535506A (ja) 2013-09-12
AU2018204190B2 (en) 2020-07-23
KR20170136009A (ko) 2017-12-08
AU2011289338B2 (en) 2015-01-22
AU2016203475A1 (en) 2016-06-16
MX2019010863A (es) 2019-11-05

Similar Documents

Publication Publication Date Title
CY2024007I1 (el) Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζονιτριλιου, φαρμακευτικες συνθεσεις που περιεχουν τετοιες ενωσεις, η χρηση τους και μεθοδοι παρασκευης τους
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2017001191A1 (es) Compuestos derivados de carbamoilpiridona policíclicos; composición farmacéutica que los comprende; y su uso para el tratamiento de una infección de vih en un humano que tiene o se encuentra en riesgo de tener la infección.
BR112013011737A2 (pt) composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv
BRPI1013394A2 (pt) &#34;composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c.&#34;
BRPI0910368A2 (pt) &#34;uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores&#34;
EA200801997A1 (ru) Новые соединения
EA200970047A1 (ru) Водные суспензии тмс278
RU2010129238A (ru) Применение производных изотиоцианата в качестве противомиеломных средств
WO2013052958A3 (en) Antimicrobial compositions and methods employing same
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2012002489A1 (es) Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c.
UY31145A1 (es) Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
EA201291394A1 (ru) Твердые композиции
CR20190006A (es) Composición y aposito para tratamiento de heridas
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
EA201300258A1 (ru) Композиции на основе налбуфина и их применение
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
BRPI0907892A2 (pt) Composto antibiótico azatricíclico, medicamento, composição farmacêutica que o contém e uso do mesmo
BRPI0814811A2 (pt) Composto, agente, método, e composição de diagnóstico, uso de um composto, e, método de formação de imagem
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
AR090569A1 (es) Agregados de nanoparticulas que contienen osteopontina y particulas que contienen calcio y/o estroncio
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
CL2013002107A1 (es) Uso de un fluido viscoelastico acuoso para producir un producto medicinal para el tratamiento quirurjico del ojo, que comprende a) por lo menos un polimero de aumento de la viscosidad a una concentracion de 0,01-30%, b) un valor de ph que oscila de 6 a 8,5 y c) una osmolaridad que oscila de 200 a 400 mosmol/l.